ArQule, Inc. has selected Nextrials, Inc.’s clinical trial data collection and management product, Prism, for use in an ongoing Phase I/II trial. ArQule will deploy Prism to replace its paper-based data collection system in a dose-escalation study of the lead product from the company’s Cancer Survival Protein (CSP) drug discovery platform. “As a biotechnology company engaged in innovative small molecule cancer research, ArQule required a more efficient and cost-effective c...